Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Amisha Barochia National Institutes of Health, Clinical Center, Critical Care Medicine Department, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]

, MBBS,

Steven Solomon National Institutes of Health, Clinical Center, Critical Care Medicine Department, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]

Xizhong Cui National Institutes of Health, Clinical Center, Critical Care Medicine Department, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]

Charles Natanson National Institutes of Health, Clinical Center, Critical Care Medicine Department, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]

Peter Q Eichacker National Institutes of Health, Clinical Center, Critical Care Medicine Department, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]

Abstract

Introduction: Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) and improve outcome when added to conventional sepsis treatments are lacking. Eritoran tetrasodium (E5564) is a promising candidate therapy for sepsis belonging to a new class of such drugs which inhibit LPS-induced inflammation by blocking toll-like receptor 4.

Areas covered: This review focuses on the rationale for the use of eritoran tetrasodium in sepsis as well as on its pharmacokinetics, pharmacodynamics, efficacy and safety. Preclinical and clinical studies from a MEDLINE/PubMed literature search in August 2010 with the search terms ‘eritoran’ and ‘E5564’ are discussed.

Expert opinion: Preclinical in vitro and in vivo studies of eritoran tetrasodium indicate it can limit excessive inflammatory mediator release associated with LPS and improve survival in sepsis models. While early clinical results are promising, its efficacy and safety for treating patients with sepsis are currently under investigation. Even if the ongoing Phase III clinical trial enrolling patients with severe sepsis and increased risk of death shows benefit from eritoran, questions remain and confirmatory studies would be necessary to define its clinical usage.

Keywords::

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Information for

Open access

Opportunities

Help and information

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Abstract

Notes

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature